Genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate Gag-specific memory CD8+ T cells ex vivo.
Mariana L PalmaTatiana M Garcia-BatesFlaviano S MartinsBruno DouradinhaPublished in: Applied microbiology and biotechnology (2019)
Recombinant Saccharomyces cerevisiae strains expressing HIV antigens have shown promising pre-clinical results. Probiotic S. cerevisiae strains naturally induce gut immunity; thus, genetically engineered probiotic strains could be used to stimulate immune responses against HIV in the mucosa. Probiotic strains have a higher rate of heterologous protein production, meaning higher antigen's epitope expression levels per yeast cell. We expressed HIV-1 Gag protein in the probiotic yeasts' surface, which was eagerly phagocytosed by and induced type 1 polarization of human monocyte-derived dendritic cells (DCs) from healthy donors in vitro. We further matured DCs derived from HIV-1+ donors with transformed yeasts and incubated them with autologous T cells. Only DCs matured with Gag-expressing probiotic strains were able to efficiently present antigen to CD8+ T cells and induced their clonal expansion. Our results show that genetically engineered probiotic S. cerevisiae strains are a promising vaccination strategy against HIV.
Keyphrases
- saccharomyces cerevisiae
- dendritic cells
- antiretroviral therapy
- hiv positive
- escherichia coli
- hiv infected
- hiv testing
- human immunodeficiency virus
- immune response
- hepatitis c virus
- endothelial cells
- hiv aids
- bacillus subtilis
- men who have sex with men
- high glucose
- lactic acid
- south africa
- regulatory t cells
- stem cells
- cell therapy
- diabetic rats
- single cell
- toll like receptor
- oxidative stress
- amino acid
- bone marrow
- inflammatory response
- long non coding rna